Tamibarotene

Drug Profile

Tamibarotene

Alternative Names: AM 80; Amnoid™; Amnolake; INNO-507; OMS0728; Retinobenzoic acid; RR 110; SY-1425; Tamibaro; TM-411; TOS-80T; Z-208

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Shionogi
  • Developer Childrens Hospital Los Angeles; CytRx Corporation; GNI; Nippon Shinyaku; Ohara Pharmaceutical; Syros Pharmaceuticals; TMRC Co. Ltd; Toko Pharmaceutical Industrial; Zeria
  • Class Antineoplastics; Benzoates; Retinoids; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor alpha agonists; Retinoic acid receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I Solid tumours
  • Preclinical Neutropenia
  • Discontinued Crohn's disease; Hepatocellular carcinoma; Non-small cell lung cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 10 Dec 2016 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 39th Annual San Antonio Breast Cancer Symposium (SABCS-2016)
  • 05 Dec 2016 Pharmacodynamics data from phase II trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 58th American Society of Hematology Annual Meeting and Exhibition (ASH-2016)
  • 05 Dec 2016 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at the 58th American Society of Hematology Annual Meeting and Exhibition (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top